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Summary The main concerns associated with epilepsy during pregnancy consist of
maternal and fetal risks from uncontrolled seizures, and harmful effects of the
treatment on the development of the offspring. Although seizure control is main-
tained in the majority, worsening occurs in a fraction of childbearing women with
epilepsy. As multiple factors associated with pregnancy may have a negative impact
on epilepsy, a careful analysis of the situation should be performed in those who
deteriorate. Emotional and behavioural influence, including insufficient sleep and
treatment non-compliance, as well as physical factors, such as emesis and pelvic
distortion, should receive attention.
The serum concentrations of almost all antiepileptic drugs decrease during
pregnancy, particularly those which are metabolised by glucuronidation. The inter-
individual variability is pronounced. In highly protein-bound drugs, such as phenytoin
and valproate, unbound drug is less affected than total concentrations. Lamotrigine
and levetiracetam concentrations may decrease by more than 50% in the course of
pregnancy; monohydroxyoxcarbazepine by up to 30—40%.
Appropriate clinical follow-up tailored to individual needs and supported by
therapeutic drug monitoring should be performed in pregnant women with epilepsy.
Education concerning reproductive issues is an essential part of the epilepsy service to
fertile women.
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Epilepsy is the most common neurological pro-
blem, which requires continuous pharmacological
treatment throughout pregnancy. Among patients,. Published by Elsevier Ltd. All rights reserved.
Epilepsy in pregnancy 161as well as among health personnel, there is still
often considerable uncertainty about the combi-
nation of pregnancy and seizure disorders, and
how these two conditions may influence each
other. The principal goal in the management of
epilepsy during pregnancy is an optimal balance
between maternal and fetal risks of uncontrolled
seizures on the one side, and the risk of fetal
exposure to antiepileptic drugs (AEDs) on the
other. In particular, generalized tonic-clonic sei-
zures should be avoided, as they may cause fetal
anoxia and dangerous injuries due to blunt abdom-
inal traumas.
Generally accepted guidelines for the treat-
ment of epilepsy in pregnant women recommend
monotherapy with the most effective AED for the
woman’s epilepsy type at the lowest effective
dose. Valproate should be avoided if there are
effective alternatives, due to potential adverse
effects on the developing fetus.1 Eager efforts
to follow these recommendations may leave some
childbearing women with a brittle seizure control.
Minimal effective treatment as a starting point
may possibly result in vulnerability to various
potential pregnancy-related seizure precipitants
(Table 1). Drug selection may be complicated in
fertile women considering seizure type and epi-
lepsy syndrome as well as the estimated terato-
genicity and the neurodevelopmental risks in
the offspring. The management of epilepsy mayTable 1 Factors which may influence seizure control
during pregnancy
Behavioural factors
Emotions (positive/negative)
Psychosocial problems
Insufficient sleep
Fear of harmful seizures, particularly during labour
and delivery
Concern for safety of breast-feeding
Misconceptions regarding the transmission of the
disorder
Worries concerning adverse effects of AEDs on the
developing fetus
Treatment non-compliance
Physical changes
Nausea and vomiting
Fatigue/exhaustion/pelvic distortion
Frequent awakenings/leg cramps
Altered hormone levels
Pharmacokinetic alterations of antiepileptic drugs
Reduced intestinal absorption
Increased volume of distribution
Altered drug protein binding
Enhanced metabolism
Increased renal clearance
Natural fluctuations of seizure frequencyindeed be complex and demanding in females who
wish to conceive.Changes in seizure control during
pregnancy
The effect of pregnancy on the course of epilepsy
has been investigated in several studies, most of
them in selected populations from specialist epi-
lepsy clinics, probably including a preponderance of
patients with difficult-to-treat seizure disorders.
Schmidt2 reviewed 2065 pregnancies reported until
1980 and concluded that the seizure frequency
increased in 24%, decreased in 23% and remained
unchanged in 53%. In a prospective study from 1983,
136 pregnancies were followed up. Seizure control
was unchanged in 50%, deteriorated in 37% and
improved in 13%.3 Later studies have reported more
or less similar findings.
Recently, a total of 1956 pregnancies in 1882
women from the EURAP pregnancy registry have
been reviewed.4 Due to lacking information from
the pre-pregnancy period, seizure control during
the second and third trimester was compared with
that of the first trimester. Unchanged seizure
frequency throughout all trimesters was reported
in as many as 64% in this survey. A total of 58%
remained completely seizure free throughout the
observation period, 68% of those with generalized
and 49% of those with partial epilepsies. Improve-
ment during the course of pregnancy was reported
in 16% and deterioration in 17%. Among the 42%
who experienced seizures, 18% had generalized
tonic-clonic seizures. Seizures during delivery
were reported in 3.5% of women. There were 36
cases of status epilepticus (2%), but only 12 of
them were convulsive. As mentioned above,
almost 60% of the EURAP participants were com-
pletely seizure free during pregnancy, a fact that
makes a marked bias towards difficult-to-treat
seizure disorders in the study population less
probable. In general, seizure control did not
appear to be worse in those pregnancies, which
resulted in miscarriages and stillbirths. Neverthe-
less, one case of status epilepticus was associated
with a miscarriage.
All these various studies indicate that pregnancy
does not appear to influence seizure control in most
women. Those who are in remission have a low risk
for recurrence during childbearing. Women who
experience changes in seizure control can be
divided in two approximately equally sized groups,
those with improvement and those with deteriora-
tion. Intensified scientific focus on the group of
women with deteriorated seizure control is now
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increase in pregnancy.Factors influencing seizure control in
pregnancy
A range of relevant factors is listed in Table 1.
Aspects other than drug-related changes have so
far received relatively little attention. It should be
kept in mind that many epilepsies seem to express
an inherent tendency to episodic fluctuations of
seizure frequency. Hence, apparent changes of sei-
zure activity during the course of pregnancy may be
due to the natural course of the epilepsy itself.
Non-pharmacokinetic factors
It is well known that the occurrence of seizures in
people with epilepsy may be intimately related to
feelings and thoughts.5 Mood and behaviour of the
expecting mother may be of significance. Pregnancy
may have a major impact on the emotional status.
‘‘Happiness is an anticonvulsant’’,5 sometimes quite
a powerful one, whereas worries and psychosocial
problems related to the pregnant state may con-
tribute to deterioration. Lack of sleep is a major
seizure precipitant in many patients. The fright for
seizures causing harm to the mother and the fetus,
particularly during labour and delivery, may be
pronounced. Future risks during care of the newborn
and limitations in the role as a mother may also
represent a threat. Uncertainty concerning the
safety of breast-feeding is prevailing. Misconcep-
tions regarding the genetic transmission of the dis-
order to the baby are widespread. Medication non-
compliance in the form of self-discontinuation of
AEDs without medical consent is not uncommon due
to maternal concern about the effects of the drugs
on the health of the unborn.6 Recurrence or worsen-
ing of seizures may be the result, a situation which
requires appropriate counselling and guidance.
Excessive nausea and vomiting during early preg-
nancymay also affect regular drug intake. Moreover,
sleep may also be disrupted from physical factors,
including leg cramps. Complications, such as pelvic
distortion may add to the physical burden towards
the end of pregnancy. All these unfavourable factors
may occur in various combinations and should be
considered in women experiencing seizure increase
during pregnancy. Relevant issues should be
addressed and discussed with the patient, appro-
priate measures to alleviate the problems should be
undertaken and rational reassurance provided.
Leave from work, domestic assistance, practical
advice and social support may be helpful. Restand protection from stress should be promoted.
Patient education including preconception counsel-
ling is important. Factual knowledge about the dis-
order and its treatment in relation to reproduction
may facilitate coping during pregnancy. Specially
trained epilepsy nurses may play an active role in
the management and support of these patients and
should be readily available for contact. A close
cooperation between professionals providing epi-
lepsy service and obstetric care is often necessary.
Pregnant women should be encouraged to share
their worries. The problems should not be trivia-
lized, but it should be emphasized that pregnancies
are successful with healthy offspring in 90% of
patients with epilepsy.7 Table 1may serve as a useful
check-list for the follow-up during pregnancy, par-
ticularly when seizure control is incomplete.
The marked increases in sex hormone levels may
also modify seizure activity. The hormonal influence
may be twofold. Hormones may interact with the
pharmacokinetics (PK) of AEDs. They may also have
a direct pharmacodynamic effect on the seizure
threshold. In animal and human studies, estrogens
generally act as proconvulsants, whereas conver-
sely, progesterone may have an anticonvulsant
effect.8 A massive and progressive increase in the
concentrations of progesterone and estrogens take
place during pregnancy. Possibly, some epilepsies
may be vulnerable to the effects of estrogen,
whereas others may be disposed to be influenced
by progestins. It is not known whether the course of
seizures during pregnancy may be predicted by the
tendency to seizure increase in relation to the
physiological hormonal fluctuations in the non-preg-
nant state, such as in so-called catamenial epilepsy.
Since the estriol/progesterone ratio rises consider-
ably during the last weeks of pregnancy,9 a correla-
tion between catamenial epilepsy and worsened
seizure control could be hypothesized. To our knowl-
edge, this has not been studied.
The induction of labour appears to be associated
with withdrawal of the inhibitory influence of pro-
gesterone on the uterine contractility.9 Several
other factors, such as stress, pain, sleep depriva-
tion, over-breathing and dehydration, may increase
the tendency to seizures during partus. Neverthe-
less, most women with epilepsy will have an
uneventful labour and a normal vaginal delivery.
However, between 3.5 and 5% may have tonic-clonic
seizures or even status epilepicus during labour or
puerperium.4 In one recent study, seizures during
labour and delivery occurred in four of 32 (12.5%)
patients categorized with primary generalized epi-
lepsy, but in none of the 57 women with partial
epilepsy.10 If tonic-clonic seizures or even status
epilepticus occur during labour, maternal hypoxia,
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for seizures should be followed closely around the
time of term.
Pharmacokinetic factors
A range of physiologic changes during gestation may
alter the PK of AEDs.11 Increased plasma volume
and/or increased total body water may lead to
increased volume of distribution, and thus reduced
AED serum concentrations. Increased plasma
volume may also result in reduced serum albumin
concentrations, which may affect AED protein bind-
ing and plasma clearance. Increased renal blood
flow and glomerular filtration rate may reduce the
serum concentrations of AEDs predominantly elimi-
nated via the kidneys. Other factors, which may
affect the PK of AED, are less well documented, e.g.
changes in gastrointestinal motility/drug absorp-
tion, and altered biotransformation capacity. In
the past three decades, several studies have been
performed regarding the AED PK during gestation.
Pregnancy-related changes may to some extent be
predicted by the pharmacological properties of
these drugs. However, the large number of factors,
which may influence serum concentrations, as well
as the marked inter-individual differences both in
drug disposition and seizure control, make clinical
reality anything else than simple. Co-medication
with enzyme-inducing or inhibiting AEDs, which
themselves may be subject to PK alterations, is a
further complicating factor. Therefore, it is often
difficult to anticipate whether pregnancy-related
changes in AED PK will become clinically relevant
in the individual patient or not.
A brief overview based on relevant literature on
the PK interaction between pregnancy and fre-
quently used AEDs is given below.
Phenobarbital (PB)
PB serum levels decrease during pregnancy. In a
study by Yerby et al.12 total serum concentrations
declined by 55% with the sharpest fall during the
first trimester. As protein binding is relatively low
(40—60%), there was a similar decline in unbound
levels (50%), but considerable inter-individual var-
iations have been demonstrated.13
Phenytoin (PHT)
PHT serum levels decrease from the start of preg-
nancy and may fall by more than 60% in the third
trimester, returning to pre-pregnancy levels within
a few weeks after delivery.14 However, a clear-cut
relation between seizure control and total serum
levels of PHT has not been established. This may be
related to changes in its free fraction. PHT is highlyprotein-bound, which makes it susceptible to
changes in plasma albumin concentrations. Accord-
ingly, an increase in its free, unbound fraction and
an increased plasma clearance of PHT during preg-
nancy, have been demonstrated. In one series,
unbound PHTserum concentrations declined by only
18%, while total PHT declined by as much as
61%.15,16 Enhanced hepatic metabolism of PHT to
its main metabolite, 5-(4-hydroxyphenyl)-5-phenyl-
hydantoin, seems to be the main cause.17 However,
one case report describes considerable intestinal
malabsorption of phenytoin during pregnancy, with
56% of the dose appearing in the faeces, leading to a
marked exacerbation of seizures and finally, status
epilepticus.18
Carbamazepine (CBZ)
Plasma clearance increases during pregnancy with a
maximum in the third trimester. The protein binding
is 70%. Total CBZ serum concentration may decline
by over 40%, but unbound drug has been reported to
be less affected.12 In one series, total CBZ levels
were only 10% lower during the third trimester
compared to baseline, whereas free concentrations
were largely unchanged (4% lower).15,16
CBZ has a pharmacologically active metabolite,
carbamazepine-10,11-epoxide. The ratio of the
epoxide metabolite to CBZ serum concentrations
usually increases during pregnancy, although not
in a predictable manner. This has been attributed
to both reduced biodegradation of the epoxide and
to its enhanced formation from CBZ.18
Altogether, clinically significant changes do not
appear to be common with CBZ during pregnancy.
Valproate (VPA)
Total VPA serum concentrations may decline by 50%
and rise to pre-pregnancy levels within one week
after delivery.12 VPA is highly protein-bound and
therefore susceptible to pregnancy-induced reduc-
tion in serum albumin concentrations. Accordingly,
the unbound fraction has been shown to be inversely
correlated to serum albumin concentrations. Since
it is the free fraction of a drug, which is pharma-
cologically active, this may outweigh the decline in
total VPA serum concentrations. It should also be
kept in mind that the free fraction increases over-
proportionally with increasing total VPA serum con-
centrations. In nine pregnancies a decrease of 39%
of total levels was found, while unbound levels
increased by 25% at delivery. Dose increase had
taken place in four of the patients.12
Lamotrigine (LTG)
LTG has a relatively low degree of protein binding
(55%) and is unlikely to be significantly affected by
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LTG is extensively metabolised, mainly to LTG-N2-
glucuronide by uridine-diphosphate glucuronosyl-
transferase (UGT). Its apparent clearance in the
last trimester of pregnancy increases to at least
the double compared to baseline, and the dose-
normalized serum concentration may be reduced
by 40—60% in the third trimester, returning to
non-pregnant levels within 1—2 weeks postpar-
tum.19—23 The fall in LTG serum concentrations is
considerably less pronounced in women on enzyme-
inducing or inhibiting co-medication,23,24 suggesting
an enhanced rate of glucuronidation as the under-
lying mechanism. Accordingly, an increased LTG-N2-
glucuronide/LTG serum concentration ratio has
recently been demonstrated during pregnancy.25
Gabapentin (GBP) and pregabalin (PGB)
GBP and PGB are not metabolised and are elimi-
nated unchanged through the kidneys. Theoreti-
cally, an increased glomerular filtration rate may
therefore lead to reduced serum concentrations.
However, no systematic studies on the PK of GBP
or PGB during the course of pregnancy have been
published.
Topiramate (TPM)
Only a small proportion of TPM is metabolised, and
up to 40% of an oral dose is eliminated unchanged via
the kidney. Thus, a pregnancy-related increase in
renal blood flow might lead to an increased renal
clearance and a decline in TPM serum concentra-
tions. No studies on the PK of TPM during pregnancy
have been published.
Oxcarbazepine (OXC)
After oral intake, OXC is quickly metabolised to the
pharmacologically active, monohydroxycarbaze-
pine (MHD-OXC), which is eliminated as a glucuro-
nide. The protein binding of MHD-OXC is less than
50%. Only two small studies on the PK of MHD-OXC
during pregnancy have been published so far. The
serum concentrations of MHD were at least 36%
lower during pregnancy, compared to pre- or post-
pregnancy values, respectively.26,27 As with LTG, an
increased rate of glucuronidation may be the
responsible mechanism.
Levetiracetam (LEV)
Protein binding is virtually non-existent. One third
of an oral dose is metabolised in blood by hydrolysis,
and two thirds are usually found unchanged in the
urine. The apparent clearance of LEV increases
significantly during pregnancy. Accordingly, case
series have demonstrated reduced serum concen-
tration/dose ratios as low as 50% of baseline.28,29The underlying mechanism is unidentified. Both
increased peripheral hydrolysis and/or increased
renal blood flow are possible.
Zonisamide (ZNS)
No systematic studies on the PK of ZNS during
pregnancy have been published. ZNS is only 60%
protein-bound and undergoes extensive biotransfor-
mation. Decreased serum albumin concentrations
and increased glomerular filtration rate would not
be expected to induce dramatic changes in the PK of
ZNS. However, other pregnancy-related changes,
like increased volume of distribution, might affect
ZNS serum concentrations. Indeed, one case report
describes an increase of the ZNS serum concentra-
tion after delivery, from 17.5 mg/mL to 23.3—
25.5 mg/mL 9 days postpartum.30Conclusion
Pregnancy does not influence seizure control in most
women with epilepsy, but a minority experiences
more seizures. Multiple mechanisms may contribute
to deterioration. Pregnancy-related behavioural
and physical factors may be of significance. Worries
related to the disorder itself may have a real basis,
but are often due to misconceptions and lack of
factual knowledge. Appropriate patient education
and counselling are crucial for confidence and treat-
ment compliance during pregnancy.
The serum concentrations of most AEDs decline
during pregnancy. In highly protein-bound com-
pounds, unbound concentrations may be less
affected than total levels. As yet, there is insuffi-
cient knowledge concerning many of the newer
AEDs, but recent studies have demonstrated reduc-
tions of LTG and LEV concentrations exceeding 50%,
and of MHD-OXC of 30—40%. The clinical conse-
quences may be enhanced when AEDs with strong
propensities to gestation-related changes are com-
bined. Pre-pregnancy serum concentrations should
be obtained and clinical follow-up during childbear-
ing should be supported by sequential measure-
ments. Dose adjustments should be performed
according to individual assessments.Conflict of interests statement
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